Can you take cagrilintide with tirzepatide?

Step 1: Understand what each medicine actually is

Tirzepatide, sold in the UK as Mounjaro, is a once-weekly injection that activates two receptors involved in appetite and blood-sugar regulation, GIP and GLP-1. It is licensed by the MHRA, recommended by NICE (TA1026), and dispensed through regulated UK pharmacies. The NHS medicines page for tirzepatide sets out how it works, its side-effect profile and who it is suitable for.

Cagrilintide is different in mechanism and status. It is a long-acting analogue of amylin, a hormone made in the pancreas alongside insulin that slows gastric emptying and reduces appetite through a separate pathway to GLP-1. Because the appetite pathways it targets are distinct, researchers have been interested in pairing it with GLP-1-based medicines, the idea being that two complementary mechanisms might produce greater weight loss than either alone.

The combination that has reached the largest published trials is CagriSema: cagrilintide 2.4 mg paired with semaglutide 2.4 mg (the dose used in Wegovy). Phase 3 results from the REDEFINE programme, reported in 2025, showed average weight loss of roughly 22% over 68 weeks. Those are striking numbers. But CagriSema is semaglutide-based, not tirzepatide-based, and it is not licensed anywhere as of mid-2026.

Step 2: See where tirzepatide fits into combination research

Researchers have looked at whether an amylin-based agent could be layered on top of tirzepatide. The logic is similar to CagriSema, tirzepatide handles the GIP/GLP-1 side, while an amylin analogue adds a third pathway. Early-stage data have appeared, but no large, published phase 3 trial of cagrilintide specifically combined with tirzepatide had reported results by mid-2026.

The MHRA licenses medicines based on completed, submitted evidence packages. Until a sponsor submits data and the MHRA grants authorisation, no UK prescriber can issue a prescription for cagrilintide in any form. That is not a technicality; it reflects how prescription-only medicines work under UK law. If you are curious about what medicines interact with tirzepatide, that is a different question, and one with concrete, licensed answers.

Novo Nordisk (which makes semaglutide) and other manufacturers are running combination trials in parallel. The landscape will likely look different in 2027 or 2028. For now, if you want a fuller picture of whether cagrilintide and tirzepatide can be taken together, the honest answer is that the combination is not something a UK prescriber can offer, because cagrilintide is not a medicine your prescriber can prescribe.

Step 3: Know what this means for your treatment choice today

If you are considering weight management treatment, the relevant question right now is which licensed medicine suits your circumstances. Tirzepatide (Mounjaro) and semaglutide (Wegovy) are both available as private prescriptions through regulated UK pharmacies, and both have substantial trial evidence behind them. The tirzepatide overview covers what SURMOUNT-1 showed (around 20–21% average weight reduction at the highest dose over 72 weeks in people without diabetes) and how eligibility works.

Some patients arrive at a consultation having read about CagriSema or combination pipelines and want to know whether waiting makes sense. That is a fair question. Trials take years to complete, licensing takes further time, and in the meantime body weight and its associated health risks are not static. A prescriber can help you think through that trade-off, not a search result. You can explore what a consultation with our prescribers involves before making any decision. If cost context matters to you, the Mounjaro price page explains what a legitimate private prescription includes.

One practical note for anyone already on tirzepatide: your pen arrives via DPD in plain packaging, tracked to your door, and once you start treatment you have access to clinical support seven days a week. The monitoring that comes with a properly supervised prescription is part of why licensed treatment matters, particularly as newer combinations eventually reach the market.

Step 4: Bookmark this for when the landscape changes

Pharmaceutical pipelines move. CagriSema has a MHRA submission pathway that could open by late 2026 or 2027 if Novo Nordisk progresses it; tirzepatide-based combinations are further behind. Pages like this will be updated as licensing status changes. Until then, any seller claiming to offer cagrilintide (alone or combined with tirzepatide) without a valid UK prescription is operating outside the law. The MHRA's Yellow Card service accepts reports of suspect sellers of prescription medicines, and using it protects other patients as well as yourself.

The honest summary: taking cagrilintide with tirzepatide is a research concept. It is not something a UK prescriber can offer today. If future licensing changes that, the clinical assessment process will look very similar to what it does now, a prescriber reviews your health picture, your current medicines, and your goals before anything is prescribed. Our clinical team is happy to discuss where you are now and which licensed options may suit you; you can find out more about the approach our prescribers take.